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ABSTRACT 
Background: The effectiveness of identifying and monitoring early-stage chronic kidney 
disease (CKD) is not fully recognised. This study quantified people with undiagnosed 
CKD among the middle-aged Japanese population and clarified potential risks of 
untreated CKD.
Methods: We included 71,233 individuals who underwent annual health check-ups 
(AHCs) in 2014 for both baseline and follow-up proteinuria and serum creatine 
measurements. CKD was identified by AHC data as proteinuria or estimated glomerular 
filtration rate (eGFR) <60 ml/min/1.73 m2. We differentiated undiagnosed from 
diagnosed CKD using the medical claims database. In undiagnosed CKD, we assessed 
risk differences for disease progression, defined as an eGFR decline slope >3 
ml/min/1.73 m2/year or proteinuria incidence over three years, between those who visited 
a physician for CKD treatment within 6 months after AHC and those who did not.
Results: CKD prevalence was 5.7% (5.2% undiagnosed and 0.5% diagnosed). Only 2.1% 
of the undiagnosed CKD patients visited a physician for CKD treatment within 6 months 
after AHC. Between-group risk differences in instrumental variable adjustment models 
showed that those left untreated progressed to kidney diseases 16.3% more often than 
those who visited physicians for CKD treatment.
Conclusion: CKD was undiagnosed in 5.2% of the middle-aged general population. Only 
a few people visited physicians for CKD treatment. Visiting physicians for CKD 
treatment during the first 6 months after screening may be associated with a lower risk of 
kidney disease progression.
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Keywords: population prevalence, early identified CKD, annual screening, instrumental 
variable analysis 
What is already known on this subject.
 Chronic kidney disease (CKD) is a condition characterized by a gradual loss of kidney function. 
 Early identification and treatment of this disease are recommended, but the effectiveness of this 
practice has been controversial.
What this study adds.
 We compared the disease outcome over three years between those who visited a physician after 
the screening for CKD and those who did not. 
 Visiting a physician after the screening for CKD was associated with a lower risk of kidney disease 
progression. 
 This finding may support an importance of ensuring a link between the positive results of renal 
screening and medical management. 
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INTRODUCTION
Chronic kidney disease (CKD) is a global health issue, affecting approximately 11–13% 
of the population across countries.[1-3] It has serious consequences on the quality of life, 
as well as on social cost when it comes to end-stage renal disease (ESRD).[4, 5] The 
number of patients with CKD is projected to further increase due to the aging population 
and increased prevalence of non-communicable diseases, such as diabetes and 
hypertension.[6] 
Given the asymptomatic nature of early-stage CKD and effective strategies to prevent or 
delay CKD progression through lifestyle modifications, public health measures to detect 
CKD using simple laboratory tests have been recommended.[7, 8] However, the 
effectiveness of identifying and monitoring early-stage CKD in primary care has not been 
fully recognised among physicians expressing concerns about the accuracy of diagnostic 
tests and overmedicalization of normality.[9, 10] Moreover, the cost-effectiveness of 
these activities in the general population has been questioned in several studies.[11-13] 
For example, a study using a cohort of simulated patients from age 50 to 90 years or 
death found that microalbuminuria screening followed by treatment with blood pressure 
lowering medications was not cost-effective for patients without diabetes and 
hypertension, unless they were conducted as part of existing physician visits.[11] 
However, we are unaware of the prevalence of undiagnosed CKD in the general 
population, nor how protective medical treatment may be against CKD progression 
followed by the identification of undiagnosed CKD in the real world. 
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This study, therefore, aimed to first quantify undiagnosed CKD detected through an 
annual health check-up (AHC) program among the middle-aged general population in 




Preventable non-communicable diseases, such as diabetes and hypertension, are assumed 
to be the underlying causes for emerging long-term care needs. In an effort to screen for 
preventable non-communicable diseases, all social health insurers in Japan have been 
required to conduct an AHC for their insureds, aged between 40 and 74 years, since 
2008.[14] The examinees were informed individually about the results after the AHC 
with medical summary and recommendations for healthy behaviors, including visiting a 
physician, were indicated as necessary. We obtained the AHC data generated between 
2011 and 2017 from the Health Insurance Association for Architecture and Civil 
Engineering companies (HIA²CE), one of the largest social health insurers that covers 
over 1800 enterprises throughout Japan, with 180,000 workers in architecture and 
engineering and their family members. The AHC data include self-reported lifestyle and 
history of diseases, measurements of abdominal circumference and blood pressure, and 
laboratory test results of urine and blood. 
To obtain information on physician visits for CKD treatment, we linked the AHC data 
with the database of insurance claims, which contains a sequential history of each insured 
person’s encounter with the healthcare system and diagnoses since September 2013. The 
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linkage was made while maintaining confidentiality by hash variables generated from 
identifiers. Further, we obtained information on the numbers of insured people of each 
enterprise.
Study population
This study included people who underwent an AHC covered by HIA²CE with proteinuria 
and serum creatine measurements in the 2014 fiscal year (FY), which is from April 2014 
to March 2015 (n=82,932). We further excluded people who had less than two serum 
creatinine values between FY2015 and FY2017 (n=11,699), resulting in 71,233 AHC 
examinees in FY2014 with outcome of interests. 
CKD was defined by either decreased GFR or kidney damage, as recommended in the 
Kidney Disease: Improving Global Outcomes (KDIGO) guidelines[15]. Decreased GFR 
was defined as GFR <60 ml/min/1.73 m2 estimated using the Japanese coefficient-
modified CKD Epidemiology Collaboration equation for GFR [16, 17] based on serum 
creatine. Kidney damage was defined as proteinuria ≥1+ using reagent strip urinalysis for 
total protein with manual reading, which corresponds approximately to urine albumin-to-
creatinine ratio ≥30 mg/g. 
Among those who were screened as CKD (n=4,053), we differentiated undiagnosed CKD 
from diagnosed CKD. The diagnosed CKD was defined as end-stage renal disease (self-
report at AHC, n=91) or as being under CKD treatment before AHC (n=261). The CKD 
treatment before AHC was identified by linking the AHC data with medical claims as an 
absence of physician visits for CKD treatment for three months before the month of the 
indexed AHC, which could vary from January 2014 to March 2015. CKD treatment was 
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defined as an outpatient physician visit for CKD-related diagnoses, the coding of which is 
required for reimbursements from payers in Japan, in medical claims shown in 
Supplementary Table 1. The selection process of the study participants is shown in 
Supplementary Figure 1.
Outcome: Progression of kidney disease over three years
Outcome of medical treatment was defined as a progression of kidney disease over three 
years (i.e., FY2014-FY2017). It was defined as a composite variable consisting of an 
eGFR decline slope greater than 3 ml/min /1.73 m2/year or an incidence of proteinuria 
among those with negative baseline proteinuria over three years. The eGFR decline slope 
was determined as an annual change estimated using an ordinary least-square regression 
model with all available eGFR measurements obtained during the three years; 63,561 
participants were included in the calculation.
Exposure variable: CKD medical treatment 
Individual variations in the timing to visit a physician for CKD medical treatment after 
the indexed AHC was also identified by linking the AHC data ith the medical claims. 
We defined our exposure variable as a physician visit for CKD-related diagnosis that 
occurred within 6 months after the AHC.
Covariates
To adjust for confounders, patient characteristics (age [numeric] and gender), eGFR 
(numeric), urine protein (-, ±, +, ++, +++, ++++), body mass index (numeric), smoking 
(binary), and comorbidities (diabetes, hypertension, history of stroke or cardiovascular 
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disease) at baseline were included as covariates. We defined diabetes as having 
hemoglobin A1c (HbA1c) level of 6.5% or higher or use of glucose-lowering drugs (self-
reported) and hypertension as having systolic blood pressure/diastolic blood pressure 
≥140/90 or use of blood pressure-lowering drugs (self-reported). 
Instrumental variables
Although observational studies have great potential for real-world comparisons of 
treatment effect and long-term outcomes, they have a variety of analytical challenges, 
such as confounding and bias, that result from differences in prognostic correlates 
between comparison groups of interest.[18] To minimise the impact of the limitations, we 
used instrumental variable (IV) analyses when assessing the association between the 
exposure variable (visiting a physician for CKD medical treatment after AHC) and the 
outcome (progression of kidney disease over three years). The likelihood of visiting a 
physician after screening is considered to be influenced by the occupational environment 
because it usually requires taking a day off from work.[19] With an assumption that these 
enterprise-level variables are likely to be unrelated to unmeasured confounders, we used 
two enterprise-level variables as IVs in the main analyses: the size of the enterprise and 
the proportion of ACH receivers per enterprise. To assess the IV assumptions, we 
reported baseline characteristics according to the instruments to estimate correlations 
between the exposure and the instrument variables (Supplementary Tables 2 and 3) and 
Montiel-Pflueger robust weak instrument tests.
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Statistical analysis
We initially described the prevalence of undiagnosed CKD and their characteristics to 
compare with non-CKD and diagnosed CKD in our study sample. Among the 
undiagnosed CKD, we drew a Kaplan-Meier plot of time to visit a physician after the 
AHC for 12 months. To compare those left untreated with those treated within 6 months 
among the undiagnosed CKD, predictive margins from logistic regressions were used to 
calculate age- and sex-adjusted prevalence ratios for risk factors. To assess associations 
of visiting a physician for CKD treatment after the AHC with the progression of kidney 
diseases over three years, a multivariable logistic model with adjustment for potential 
confounders was used. In the IV analysis, a two-stage residual inclusion approach was 
applied.[20] In the first stage, we used a logistic regression model with our exposure 
variable as a dependent variable, and the enterprise-level Ivs and measured confounders 
as independent variables. Using the first-stage model, we estimated the residual for each 
person. In the second stage, we applied a logistic model with the progression of kidney 
disease as a dependent variable, and the exposure variable, residual from the first-stage 
model, and measured confounders as independent variables. We computed estimates of 
the adjusted risk differences with delta-method standard errors for each exposure 
category.[21]
Sensitivity analysis
We performed three sensitivity analyses. First, CKD definition was redefined as CKD 
confirmed both in 2013 AHC and 2014 AHC. This analysis reduced the analytic sample 
to 1,181. Second, since the amount of eGFR reduction rate that is clinically important 
varies among studies, we carried out a sensitivity analysis with eGFR slope decline 
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alternatively defined as greater than 5 ml/min/1.73 m2/year. Third, we used another 
enterprise-level IV to capture how much more or less than expected people visit a 
physician in their working place on average in the 3 months before AHC, the methods of 
which were used in a clinical epidemiological study to assess a selection of psychological 
therapy.[22] For this IV, we calculated the ratios for each enterprise and for each month 
between the observed number of CKD medical treatment and the expected numbers that 
were predicted from a logistic regression model, including gender, age, and morbidity 
(diabetes mellitus, hypertension, history of stroke, and cardiovascular disease) of the 
entire AHC examinees. Baseline characteristics according to quintiles of the instrument 
are reported in Supplementary Table 4. All analyses were performed using Stata, version 
15.1 (StataCorp®, College Station, TX, USA). All tests were 2-sided with p-values <0.05 
considered statistically significant.
Institutional review board approval 
The Institutional Review Board (IRB) of Kyoto University approved the study (R0817). 
We analyzed the data anonymously, and the IRB waived informed and signed consent for 
this observational study from each participant. This research was conducted in 
accordance with the principles embodied in the Declaration of Helsinki.
RESULTS
The prevalence of CKD screened in 2014 AHC was 5.68% (95% confidence interval 
[CI], 5.52 to 5.86), with 5.19% undiagnosed CKD (95% CI, 5.03 to 5.36) and 0.49% 
diagnosed CKD (95% CI, 0.44 to 0.54). Table 1 describes the characteristics of those 
without CKD (n=67,180), those with undiagnosed CKD (n=3,701), and those with 
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diagnosed CKD (n=352). People with CKD were older, more obese and had more 
comorbid conditions compared with those without CKD. No notable differences were 
found in the demographics and comorbid conditions between undiagnosed and diagnosed 
CKD, except more people with diagnosed CKD were under medication and had history 
of diseases. Either an eGFR decline defined as 3 ml/min/1.73 m2/year or greater or an 
incidence of proteinuria over three years was observed in over 30% of those with 
diagnosed CKD, while it was 15% among those with undiagnosed CKD.






















Age mean (SD) 50.6 (7.6) 53.7 (8.5) 54.2 (8.1)
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BMI mean (SD) 23.7 (3.6) 25.4 (4.2) 25.8 (4.1)
Systolic blood pressure
 ≥140 mmHg, % 15.7 27.0 27.8
SBP mean (SD) 124.3 
(16.7)
130.8 (19.0) 130.9 (18.9)
Diastolic blood pressure
 ≥90 mmHg, % 14.2 24.8 19.0
DBP mean (SD) 77.2 (11.2) 82.0 (12.7) 79.9 (11.7)
HbA1c
 ≥6.5%, % 5.8 16.7 32.4
HbA1c mean (SD) 5.58 (0.64) 5.93 (1.10) 6.28 (1.29)
eGFR group, %
  ≥90 18.4 10.6 5.4
 60–89 81.6 50.4 22.2
 45–59 0.0 39.0 72.4








History of cardiovascular 
disease/stroke, %
2.9 6.2 13.4
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Smoking, % 29.3 32.5 25.3
Progression of renal 
disease, %
omposite outcome 12.1 15.0 31.8
eGFR slope decline a 9.1 13.5 27.9
Proteinuria incidence b 5.5 9.0 26.0
Notes: a eGFR decline was defined as 3 ml/min/1.73 m2/year or a greater decrease 
described by the individual participant slope of eGFR during the 3-year follow-up. 
b Excluded participants with proteinuria at baseline. n=58,217 for non-CKD, 1,150 for 
undiagnosed CKD, 102 for diagnosed CKD
Abbreviations: CKD, chronic kidney disease; BMI, body mass index; HbA1c, 
hemoglobin A1c; eGFR, estimated glomerular filtration rate
The prevalence of medical treatment provided after the indexed AHC among those with 
undiagnosed CKD is described in Figure 1. Only 2.13% (95% CI, 1.69 to 2.65) of them 
visited a physician seeking CKD treatment within 6 months after AHC. The prevalence 
slightly increased to 3.57% (95% CI, 2.99 to 4.21) within 12 months. 
Table 2 shows age- and sex-adjusted prevalence ratios for risk factors for left untreated 
CKD among those with undiagnosed CKD. The risk factors were almost identically 
distributed between left untreated and treated CKD. 
Table 2 Age- and sex-adjusted prevalence ratios for risk factors for left untreated CKD 
(n=3,701)
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Characteristics Crude prevalence, 
%


















































 No 98.23 1.00 (reference)
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Abbreviations: CI, confidence interval; CKD, chronic kidney disease; BMI, body mass 
index; HbA1c, hemoglobin A1c
Progression of kidney disease was observed in 20.3% (n=16/79, 95% CI, 12.0 to 30.8) of 
those being treated and in 14.9% (n=539/3,622, 95% CI, 13.7 to 16.1) of those left 
untreated. Between-group risk differences for the progression of kidney disease were not 
observed in both age- and sex-adjusted models and multivariate-adjusted models. 
However, the IV-adjusted models showed that those left untreated were more likely to 
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progress to kidney disease (Table 3). The results were similar when each outcome was 
evaluated separately.
Table 3 Associations between medical treatment and progression of renal disease among 
people with undiagnosed CKD























16 20.3 (12.0 
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Notes: a Risk differences were estimated from logistic regression models with the 
progression of kidney disease as a dependent variable with treated within 6 months as a 
reference. Positive values indicate a higher probability of progression of kidney disease 
for people left untreated.
b Adjusted for gender, age (numeric), baseline eGFR (numeric), baseline proteinuria 
(binary), baseline body mass index (numeric), baseline diabetes mellitus (binary), 
baseline hypertension (binary), baseline smoking status (binary), history of stroke 
(binary), and history of cardiovascular disease (binary).
c Instrumental variable analysis via a two-stage residual inclusion approach using 
enterprise-level variables as instruments. Weak instrument was tested using the Montiel-
Pflueger robust weak instrument test (confidence level alpha=0.05) with effective F 
statistics.
d eGFR decline was defined as 3 ml/min/1.73 m2/year or a greater decrease described by 
the individual participant slope of eGFR during the 3-year follow-up. 
e Excluded participants with proteinuria at baseline (n=1,427), participants treated within 
6 months (n=22), and participants left untreated (n=1,130)
Abbreviations: CKD, chronic kidney disease; RD, risk difference; CI, confidence 
interval; IV, instrumental variable; eGFR, estimated glomerular filtration rate
Sensitivity analyses with restricted samples of those with CKD were confirmed through 
two consecutive AHCs (i.e., 2013 and 2014), with an alternative outcome definition as 5 
ml/min/1.73 m2 or greater of eGFR slope annual decline, and with an alternative IV 
showed almost identical results to the main findings (Supplementary Table 5).
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DISCUSSION
This study shows that undiagnosed CKD was screened in 5.2% of the middle-aged 
population and only a few of those with undiagnosed CKD visited a physician for CKD 
treatment within 6 months (2.1%) and 12 months (3.6%) after the screening. The average 
effect of medical treatment among the subgroup of participants for whom their work 
place determines its health seeking behaviour indicates that people with undiagnosed 
CKD had a lower risk of progressing kidney disease if they visited a physician for CKD 
treatment during the first 6 months after the screening. 
The high prevalence of untreated CKD may indicate people’s poor engagement with their 
health. Administrative efforts by health insurers are being made with the aim to improve 
healthy behaviors using, for example, health behavioural science; however, their focus is 
currently on increasing the number of examinees of AHC and not on ensuring a linkage 
between positive AHC results and medical management. Our study may support the 
importance of such linkage; therefore, developing an effective strategy is warranted.[23] 
The prevalence of CKD found in this study was <6%, which was relatively low compared 
to the previously estimated global prevalence of CKD that is between 11% and 13%.[3] 
Although the CKD definition is slightly different between the studies, we assume that the 
main cause was most likely to be our sample characteristics, which did not include an 
older population. Furthermore, we analyzed only data from participants whose baseline 
and follow-up CKD-related data were available, which would have resulted in our sample 
to be slightly healthier than the age adjusted general population (Supplementary Table 6).
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We found that people are most likely to be undiagnosed when CKD is detected at an 
annual screening unless they are already under medication for diabetes or hypertension at 
the screening. The result is in concordance with that of a US study using both Medicare 
claims and research study measurements to define CKD.[24] It shows that individuals 
with CKD identified in claims had a more risky profile than those with CKD identified 
by study measurements.
The strengths of our study include the use of a large longitudinal health data including 
self-reported information on lifestyle and blood/urine tests that were linked to the medical 
claims database and external information on the number of insureds for each enterprise. 
This allowed us to choose individuals with undiagnosed CKD and investigate if medical 
treatment is associated with their progression of kidney disease for three years accounting 
for their working environment.
This study has several limitations that should be considered when interpreting the results. 
First, we identified physician visits for CKD treatment using the code of diagnoses that 
appeared on medical insurance claims, and we do not know what “medical treatment” 
was provided at the visit. Treatment strategies for CKD are diverse depending on 
individual situations that may include a variety of recommendations for lifestyle changes 
and/or medication to treat or prevent the different problems caused by CKD. We could 
not specify what element of physician visit was effective to prevent the progression of 
kidney disease. It may be worthwhile for future researches to investigate what element of 
treatment should be provided for protection of kidney function and how we can improve 
health seeking behaviors after CKD screening in the general population.
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Second, our instrument variables were not sufficiently strong (F statistics <10.0); they 
explain only a small proportion of the variations of physician visits. Using IV has a 
potential to control for unmeasured confounders, but at least three important prerequisites 
must be fulfilled: 1) the relevance assumption: the instrument has a causal effect on the 
exposure; 2) the exclusion restriction: the instrument affects the outcome only through 
the exposure; and 3) the exchangeability assumption: the instrument does not share 
common causes with the outcome.[25] Observational studies often face a weak 
association between instrument and exposure, as observed in our data; therefore, careful 
scrutiny of the exchangeability and the exclusion restriction is needed. Although these 
requirements cannot be directly verified in the data, the exchangeability assumption is 
partially verifiable in the data using measured covariates; the measured covariates were 
rather balanced between the quintiles of different instruments (Supplementary Tables 2-
4). We would like to argue that the exclusion restriction was also met, but we could not 
fully rule out the possibility of any direct effect of the instrument on outcome. On the 
other hand, as we observed a substantially high prevalence of renal progression among 
those who had been under medical treatment at the screening (30% compared to 15% 
among those undiagnosed), it is the nature of observational studies that estimations of 
effectiveness of any treatment are likely to be biased by unmeasured confounding. In 
addition, we obtained similar results even with different IVs, alternative outcomes, and 
restricted samples in the sensitivity analyses. Considering the above points, it may not be 
too overstated that the standard regression analyses favouring the untreated group was 
likely due to unobservable characteristics of the participants that influenced whether they 
received treatment. 
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Third, damaged kidney function was measured by urine reagent strips, not by improved 
albuminuria, because it is the standard procedure adopted in AHC. KDIGO guidelines 
state that urine reagent strip results can be substituted when albuminuria measurements 
are not available. However, urine albumin measurements can provide a more specific and 
sensitive measure of changes in glomerular permeability than urinary total protein. 
Fourth, a possible bias of population should be considered. Although our participants 
belong to a specific social insurer of architects and engineers, which covers a range of 
socioeconomic status hierarchies, we confirmed that they are only slightly healthier than 
the age-adjusted general population of Japan. However, careful consideration is needed 
when we apply our results to other countries. 
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Figure legend
Cumulative probability of medical treatment depicted using the Kaplan-Meier plot of 
time to visit a physician for chronic kidney disease (CKD) treatment after the indexed 
annual health check-up (AHC) for 12 months.
 
Abbreviations: AHC, annual health check-up
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Fig.1 Medical treatment after AHC
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Supplementary Table 1 CKD-related diagnosis codes in ICD-10  
 
 ICD-10_1 codes 
Chronic kidney disease 
N170, N171, N172, N178, N179, N180, N188, 
N189, N19, N990 
Tubulo-interstitial nephritis 
N110, N111, N118, N119, N12, N140, N141, 
N142, N143, N144, N150 
Chronic glomerular nephritis 
N002, N003, N004, N006, N007, N009, N012, 
N014, N016, N017, N019, N028, N029, N030, 
N032, N033, N034, N036, N037, N039, N040, 
N042, N044, N046, N049, N050, N051, N052, 
N053, N054, N055, N056, N057, N058, N059, 
N069, N079, N085 
Diabetic nephropathy E102, E112, E132, E142 
Hypertensive nephrosclerosis I129, I120 
Polycystic kidney disease Q613 
 
CKD, chronic kidney disease; ICD-10, International Classification of Diseases, 10th revision 
 
Page 28 of 34
https://mc.manuscriptcentral.com/jech





























































Confidential: For Review Only
Supplementary Table 2 Baseline characteristics of cohort across categories of IV variable: size of 
enterprise 
 <50 ≥50, <300 ≥300 







Number of people 459 1131 2672 
Medical treatment 1.53 2.56 2.32 
Age (years)    
 40-49 25.27 28.90 39.41 
 50-59 31.79 33.01 34.26 
 60- 42.93 38.08 26.33 
Male 88.0 90.15 87.23 
Proteinuria 62.40 64.64 66.50 
eGFR (ml/min)    
 <60 43.20 39.81 38.14 
 60-90 48.53 48.31 51.30 
 ≥90 8.27 11.88 10.56 
Systolic blood pressure ≥140 mmHg 35.47 33.87 23.79 
Diastolic blood pressure ≥90 mmHg 26.93 27.53 23.75 
HbA1c ≥6.5% 18.38 19.70 15.63 
BMI    
 <22.9 23.73 25.51 27.39 
 23-27.4 51.20 44.26 47.39 
 ≥27.5 25.07 30.23 25.22 
Antihypertensive drugs 39.73 39.41 31.80 
Anti-diabetic drugs 12.53 13.23 11.14 
Anti-hyperlipidemic drugs 16.53 19.57 18.65 
History of cardiovascular disease/stroke 5.60 5.94 6.34 
Smoking 40.53 37.38 29.90 
 
IV, instrumental variable; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; 
BMI, body mass index 
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Supplementary Table 3 Baseline characteristics of cohort across quintiles of IV variable: 
proportion of AHC receivers 
 1 2 3 4 5 












Number of people 788 836 593 740 734 
Medical Treatment   1.52 1.56 2.53 2.70 2.59 
Age (years)      
 40-49 37.02 38.35 41.13 32.24 31.40 
 50-59 35.75 34.47 30.55 33.06 34.30 
 60- 27.23 27.18 28.33 34.71 34.30 
Male 84.14 85.65 92.07 88.38 91.14 
Proteinuria 62.18 64.59 71.16 63.51 68.80 
eGFR(ml/min)      
 <60 41.37 40.07 32.71 41.76 37.33 
 60-90 49.71 48.56 54.81 49.59 51.23 
 >=90 9.39 11.36 12.48 8.65 11.44 
Systolic Blood Pressure 140
≦ mmHg 
20.30 26.91 24.45 29.59 33.38 
Diastolic Blood Pressure 90
≦ mmHg 
19.42 25.12 26.64 25.68 27.93 
HbA1c  6.5≦ % 14.91 15.38 16.07 16.64 20.85 
BMI      
 <22.9 26.90 28.11 25.13 28.78 23.71 
 23-27.4 45.05 46.29 50.93 46.62 47.68 
 27.5≦ 28.05 25.60 23.95 24.59 28.61 
Antihypertensive drugs 34.90 34.57 30.35 33.11 37.06 
Anti-diabetic drugs 12.06 9.33 10.46 12.03 14.85 
Anti-hyperlipidemic drugs 17.89 18.78 15.35 21.08 19.35 
History of cardiovascular 
disease/stroke 
7.23 6.22 5.40 7.43 4.50 
Smoking 30.58 31.34 33.22 30.41 37.33 
IV, instrumental variable; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; 
BMI, body mass index 
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Supplementary Table 4 Baseline characteristics of cohort across quintiles of IV variable: 
observed/expected 
 1 2 3 4 5 
Median of instrument 
(range) 
0.00 (0.00 to 
0.24) 
0.39 (0.24 to 
0.50) 
0.59 (0.50 – 
0.68) 




Number of people 741 743 826 668 723 
Medical treatment 1.89 1.75 1.45 3.74 2.07 
Age (years)      
 40-49 27.73 40.84 40.79 37.20 32.35 
 50-59 33.47 35.14 34.15 32.23 33.61 
 ≥60 38.80 24.02 25.06 30.57 34.04 
Male 87.99 88.83 84.38 89.52 89.76 
Proteinuria 62.21 66.62 64.53 68.41 67.22 
eGFR (ml/min)      
 <60 42.78 38.22 38.86 36.68 38.17 
 60-90 48.45 50.61 50.36 51.95 50.90 
 ≥90 8.77 11.17 10.77 11.38 10.93 
Systolic blood pressure 
≥140 mmHg 
33.47 24.90 22.88 26.65 27.52 
Diastolic blood pressure ≥90 
mmHg 
26.32 25.17 23.61 24.55 24.62 
HbA1c ≥6.5% 17.53 17.00 15.38 17.29 16.60 
BMI      
 <22.9 25.10 25.98 28.69 25.75 27.39 
 23-27.4 47.64 45.36 46.73 48.65 47.58 
 ≥27.5 27.26 28.57 24.58 25.60 25.03 
Antihypertensive drugs 37.79 32.71 30.87 34.88 34.85 
Anti-diabetic drugs 13.50 10.77 10.63 12.72 11.07 
Anti-hyperlipidemic drugs 16.87 17.63 18.40 21.71 18.81 
History of cardiovascular 
disease/stroke 
6.61 6.06 5.21 7.34 5.95 
Smoking 36.57 28.13 28.45 35.78 34.30 
IV, instrumental variable; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; 
BMI, body mass index  
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Supplementary Table 5 Sensitivity analyses  
 
Restricted sample to people with CKD confirmed through consecutive two years 
(n=1,181) 
eGFR slope decline 
alternatively defined 
as 5 mL/min/1.73 









Age and sex 
adjusted 
Adjusted* IV Adjusted** IV Adjusted** IV Adjusted** 
RD† (95% CI) RD† (95% CI) RD† (95% CI) RD† (95% CI) RD† (95% CI) 
Composite 
outcome 
20.5 (9.3 to 
36.5) 




6.45 (-2.88 to 
15.78) 
21.47 (8.57 to 
34.57) 
8.80 (7.95 to 9.64) 




21.6 (9.8 to 
38.2) 








6.63 (5.93 to 7.32) 




0 (0.0 to 
28.5) 
9.8 (7.3 to 
12.6) 
-   10.39 (8.79 to 11.99) 
10.35 (8.76 to 
11.94) 
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; IV, instrumental variable; RD, risk difference; CI, confidence interval 
*Adjusted for gender, age (numeric), baseline eGFR (numeric), baseline proteinuria (binary), baseline body mass index (numeric), baseline diabetes 
mellitus (binary), baseline hypertension (binary), baseline smoking status (binary), history of stroke (binary), and history of cardiovascular disease 
(binary) 
**‡Instrumental variable analysis via a two-stage residual inclusion approach using enterprise-level variables as instruments. Weak instrument was 
tested using the Montiel-Pflueger robust weak instrument test (confidence level alpha=0.05) with effective F statistics. 
†Risk differences were estimated from logistic regression models with progression of kidney disease as a dependent variable with treated within 6 
months as a reference. Positive values indicate a higher probability of progression of kidney disease for people left untreated. 
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Supplementary Table 6 Characteristics of the study population and the Japanese general 
population 
 Study population 
N=71,233 
 Age-standardized* 





 Male Female 
Age categories, %      
  40-49 49.3%  43.5% 
  50-59 33.4%  36.5% 
  60-65 17.2%  20.0% 
Antidiabetic drugs, % 5.9 % 1.1 %  6.5% 2.7% 
Antihypertensive drugs, % 18.2% 7.5 %  21.0% 12.0% 
SBP, mean, mmHg 126.9 118.1  131.8 123.3 
DBP, mean, mmHg 79.7 70.8  83.9 76.6 
HbA1c, mean, % 5.6 5.5  5.7 5.6 
SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c 
*Adjusted for the 2017 age-gender distribution of the Japanese population aged 40–64 years. 
We extracted data from the online portal website for the official statistics of Japan 
(http://www.e-stat.go.jp/). 
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